Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Local drug delivery to prevent restenosis.

Seedial SM, Ghosh S, Saunders RS, Suwanabol PA, Shi X, Liu B, Kent KC.

J Vasc Surg. 2013 May;57(5):1403-14. doi: 10.1016/j.jvs.2012.12.069. Review.

2.

Paclitaxel-eluting balloon: from bench to bed.

De Labriolle A, Pakala R, Bonello L, Lemesle G, Scheinowitz M, Waksman R.

Catheter Cardiovasc Interv. 2009 Apr 1;73(5):643-52. doi: 10.1002/ccd.21895. Review.

PMID:
19309715
3.

[Recent progress in application of local drug delivery for preventing restenosis after peripheral arterial revascularization].

Zhang M, Zhang F, Zhang H, Liang G.

Zhonghua Wai Ke Za Zhi. 2015 Mar;53(3):237-40. Review. Chinese.

PMID:
26269021
4.

Drug-eluting balloon: the comeback kid?

Waksman R, Pakala R.

Circ Cardiovasc Interv. 2009 Aug;2(4):352-8. doi: 10.1161/CIRCINTERVENTIONS.109.873703. Review. No abstract available.

5.

Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.

Doostzadeh J, Clark LN, Bezenek S, Pierson W, Sood PR, Sudhir K.

Coron Artery Dis. 2010 Jan;21(1):46-56. doi: 10.1097/MCA.0b013e328333f550. Review.

PMID:
19952925
6.

Targeted vascular drug delivery. A new day for an old way.

Buchbinder M, Solar R.

Panminerva Med. 2013 Dec;55(4):353-61. Review.

PMID:
24434344
7.

Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.

Kufner S, Cassese S, Valeskini M, Neumann FJ, Schulz-Schüpke S, Hoppmann P, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A, Byrne RA; ISAR-DESIRE 3 Investigators.

JACC Cardiovasc Interv. 2015 Jun;8(7):877-84. doi: 10.1016/j.jcin.2015.01.031. Epub 2015 May 20.

8.

Advances on drug-coated balloons.

Tepe G, Schmitmeier S, Speck U, Schnorr B, Kelsch B, Scheller B.

J Cardiovasc Surg (Torino). 2010 Feb;51(1):125-43. Review.

PMID:
20081769
9.

Drug-eluting stents.

García-García HM, Vaina S, Tsuchida K, Serruys PW.

Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Review.

PMID:
17091802
10.

Eluting combination drugs from stents.

Thipparaboina R, Khan W, Domb AJ.

Int J Pharm. 2013 Sep 15;454(1):4-10. doi: 10.1016/j.ijpharm.2013.07.005. Epub 2013 Jul 10. Review.

PMID:
23850234
11.

Drug delivering technology for endovascular management of infrainguinal peripheral artery disease.

Sarode K, Spelber DA, Bhatt DL, Mohammad A, Prasad A, Brilakis ES, Banerjee S.

JACC Cardiovasc Interv. 2014 Aug;7(8):827-39. doi: 10.1016/j.jcin.2014.05.008. Review.

12.

Lesions in small coronary vessels disease: should drug-coated balloons replace drug-eluting stents as the treatment of choice?

Byrne RA, Kastrati A.

EuroIntervention. 2011 May;7 Suppl K:K47-52. doi: 10.4244/EIJV7SKA8.

PMID:
22027727
13.

Understanding the drug-eluting stent trials.

Coolong A, Kuntz RE.

Am J Cardiol. 2007 Sep 3;100(5A):17K-24K. Epub 2007 Jun 26. Review.

PMID:
17719349
14.

12-month primary patency rates of contemporary endovascular device therapy for femoro-popliteal occlusive disease in 6,024 patients: beyond balloon angioplasty.

Marmagkiolis K, Hakeem A, Choksi N, Al-Hawwas M, Edupuganti MM, Leesar MA, Cilingiroglu M.

Catheter Cardiovasc Interv. 2014 Oct 1;84(4):555-64. doi: 10.1002/ccd.25510. Epub 2014 May 8. Review.

PMID:
24740749
15.

Macromolecular approaches to prevent thrombosis and intimal hyperplasia following percutaneous coronary intervention.

Scott RA, Panitch A.

Biomacromolecules. 2014 Aug 11;15(8):2825-32. doi: 10.1021/bm5007757. Epub 2014 Jul 8. Review.

16.

Drug eluting balloons.

Diehm NA, Hoppe H, Do DD.

Tech Vasc Interv Radiol. 2010 Mar;13(1):59-63. doi: 10.1053/j.tvir.2009.10.008. Review.

PMID:
20123434
17.

Comparative vascular responses three months after paclitaxel and everolimus-eluting stent implantation in streptozotocin-induced diabetic porcine coronary arteries.

Sheehy A, Hsu S, Bouchard A, Lema P, Savard C, Guy LG, Tai J, Polyakov I.

Cardiovasc Diabetol. 2012 Jun 21;11:75. doi: 10.1186/1475-2840-11-75.

18.

Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).

Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C, Cangiano E, Minarelli M, Scalone A, Cavazza C, Marchesini J, Parrinello G; PRODIGY Investigators.

JACC Cardiovasc Interv. 2014 Jan;7(1):20-8. doi: 10.1016/j.jcin.2013.09.008. Epub 2013 Dec 11.

19.

First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).

Ormiston J, Webster M, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knape C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W.

JACC Cardiovasc Interv. 2013 Oct;6(10):1026-34. doi: 10.1016/j.jcin.2013.05.013. Epub 2013 Sep 18.

20.

Drug-eluting stents and drug-coated balloons in peripheral artery disease.

Buechel R, Stirnimann A, Zimmer R, Keo H, Groechenig E.

Vasa. 2012 Jul;41(4):248-61. doi: 10.1024/0301-1526/a000200. Review.

PMID:
22825858

Supplemental Content

Support Center